BioCentury | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Feb 22, 2018
Targets & Mechanisms

Molecular mentality

A Science study of gene expression signatures in psychiatric disease patients is the field’s largest transcriptomic readout to date, moving it closer toward molecular characterization of mental disorders. By helping map targets and pathways, the...
BioCentury | Mar 23, 2017
Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; peptides A genomic and proteomic screening method could identify neoantigens as personalized immunotherapy targets for cancer. The method involved collecting tumor and non-tumor tissue samples from a patient; immunoprecipitating human leukocyte antigen...
BioCentury | Mar 22, 2017
Clinical News

Stanford neoantigen pipeline finds Ig targets in lymphoma

In a study published Wednesday in Nature , a Stanford University team's neoantigen identification pipeline showed patient-specific, or "idiotypic," immunoglobulin peptides were presented on human leukocyte antigen (HLA) class II molecules in mantle cell lymphoma (MCL)...
BioCentury | Mar 10, 2016
Tools & Techniques

Ziopharm bets on the HLA-A odds

Ziopharm Oncology Inc. is adding gene editing to its repertoire with a strategy to increase the odds of finding a match for hematopoietic stem cell transplants. While the system is still short of an allogeneic...
BioCentury | Feb 4, 2016
Clinical News

Vanderbilt team finds new biomarker of anti-PD-1 sensitivity

A Vanderbilt University research team has identified a biomarker for predicting sensitivity to anti- PD-1 therapies in melanoma patients. The authors suggested that the biomarker could be cheaper and easier to measure than other biomarker...
BioCentury | Jan 4, 2016
Clinical News

IMMU-114: Phase I data

Data from 6 evaluable patients with NHL or CLL in an open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly subcutaneous 200 mg IMMU-114 led to 1 complete response and 3 partial responses. The once-weekly...
BioCentury | Apr 23, 2015
Distillery Techniques

Techniques: CD4+ T cell markers of active tuberculosis for diagnosis and monitoring treatment responses

Biomarkers TECHNOLOGY: Plasma markers Markers of immune activation on Mycobacterium tuberculosis-specific T cells could help diagnose active tuberculosis and monitor treatment responses. In blood from a cohort of patients whose tuberculosis was diagnosed by sputum...
Items per page:
1 - 10 of 86